Nabriva Therapeutics AG

Nabriva Therapeutics — Investor Presentation (November 2015)

17 slides from Nabriva Therapeutics's investor presentation, Nov 10, 2015

  1. Slide 1: Forward-Looking Statements

    Slide 1: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi

  2. Slide 2: Colin Broom, MD, Chief Executive Officer

    Slide 2: Colin Broom, MD, Chief Executive Officer

    3 Colin Broom, MD Chief Executive Officer Nabriva Therapeutics AG

  3. Slide 3: Nabriva Corporate Strategy

    Slide 3: Nabriva Corporate Strategy

    Nabriva Corporate Strategy Become a Fully Integrated Company Focused on Novel Antibiotics for Serious Infections Complete Phase 3 trials and obtain regulatory approval of lefamulin for Community Acquired Bacterial Pneumonia (CABP) Maximize the commercial potential of lefamulin for CABP Pursue the de

  4. Slide 4: Lefamulin 2015 Highlights

    Slide 4: Lefamulin 2015 Highlights

    Lefamulin 2015 Highlights Pleuromutilins – new class of antibiotics in development for systemic use in humans Novel mechanism of action with potent in vitro activity against multi-drug resistant strains Proprietary platform and IP wholly owned by Nabriva with extensive in-house expertise Lefamulin -

  5. Slide 5: Nabriva's Pleuromutilin Pipeline is Advancing

    Slide 5: Nabriva's Pleuromutilin Pipeline is Advancing

    Nabriva’s Pleuromutilin Pipeline is Advancing Program Indications Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Comments Lefamulin (IV/oral) CABP* IV/Oral Phase 3 initiated; Oral Phase 3 initiation planned 1Q16 ABSSSI Phase 2 complete Lefamulin (IV/oral) Pediatric Indications Preclinical work and f

  6. Slide 6: Elyse Seltzer, MD, Chief Medical Officer

    Slide 6: Elyse Seltzer, MD, Chief Medical Officer

    7 Elyse Seltzer, MD Chief Medical Officer Nabriva Therapeutics AG

  7. Slide 7: Clinical Development Plan for Differentiation in CABP

    Slide 7: Clinical Development Plan for Differentiation in CABP

    Clinical Development Plan for Differentiation in CABP Phase 3 CABP registration program initiated in the fall of 2015 Lefamulin Evaluation Against Pneumonia (LEAP) trial (IV to oral) in patients with moderate-to-severe CABP (PORT III and above) Second study (oral) in moderate CABP (PORT II to IV) Ex

  8. Slide 8: LEAP IV to Oral Powering and Primary Objectives

    Slide 8: LEAP IV to Oral Powering and Primary Objectives

    LEAP IV to Oral Powering and Primary Objectives LEAP has 90% power to establish the non-inferiority (NI) of lefamulin to moxifloxacin for both FDA and EMA endpoints using a NI margin of 10% Demonstrate the NI of lefamulin versus comparator with respect to Early Clinical Response , (96 ± 24 hours aft

  9. Slide 9: LEAP IV to Oral Trial Design

    Slide 9: LEAP IV to Oral Trial Design

    LEAP IV to Oral Trial Design Phase 3: Double-blind, double-dummy; active-controlled Population Approximately 740 adult patients with CABP Pneumonia Outcomes Research Team (PORT) Risk Class >III (moderate to severe) Approximately 100 international centers 1:1 randomization - lefamulin v comparator (m

  10. Slide 10: LEAP IV to Oral Treatment Scenarios

    Slide 10: LEAP IV to Oral Treatment Scenarios

    LEAP IV to Oral Treatment Scenarios All subjects begin with IV therapy for a minimum of three days before switching to oral therapy Majority of patients will receive 5 days of lefamulin v 7 days moxifloxacin If CABP caused by 1) S. pneumoniae with accompanying bacteremia or 2) L. pneumophila, both t

  11. Slide 11: LEAP IV to Oral Switch Criteria

    Slide 11: LEAP IV to Oral Switch Criteria

    LEAP IV to Oral Switch Criteria Subjects will be permitted to switch from IV to oral study drug if all of the following criteria are met: Have received 3 days (6 doses) of IV therapy Are hemodynamically stable Have a normalizing temperature Have demonstrated improvement in at least 1 severity catego

  12. Slide 12: Ralf Schmid, Chief Operating Officer and Chief Financial Officer

    Slide 12: Ralf Schmid, Chief Operating Officer and Chief Financial Officer

    13 Ralf Schmid Chief Operating Officer and Chief Financial Officer Nabriva Therapeutics AG

  13. Slide 13: Initial Public Offering of American Depositary Shares Completed in September 2015

    Slide 13: Initial Public Offering of American Depositary Shares Completed in September 2015

    Initial Public Offering of American Depositary Shares (NASDAQ:NBRV) Completed in September 2015 We sold a total of 10,350,000 ADSs at an offering price of $10.25 per ADS Each ADS represents one tenth (1/10) of a common share 2,098,972 common shares outstanding on September 30, 2015 Upon the closing

  14. Slide 14: Colin Broom, MD, Chief Executive Officer

    Slide 14: Colin Broom, MD, Chief Executive Officer

    16 Colin Broom, MD Chief Executive Officer Nabriva Therapeutics AG

  15. Slide 15: Anticipated Key Milestones

    Slide 15: Anticipated Key Milestones

    Anticipated Key Milestones October 2015: First Phase 3 clinical trial for the treatment of CABP initiated 1Q 2016: Second Phase 3 clinical trial for the treatment of CABP to be initiated 2H 2017: Top-line data available for both Phase 3 trials for the treatment of CABP 2018: Submission of a NDA to t

  16. Slide 16: Nabriva Summary

    Slide 16: Nabriva Summary

    Nabriva Summary Developing novel antibiotics for serious infections Pleuromutilins – new class of antibiotics in development for systemic use in humans Novel mechanism of action with potent in vitro activity against multi-drug resistant strains Proprietary platform and IP wholly owned by Nabriva wit

  17. Slide 17: Nabriva Summary

    Slide 17: Nabriva Summary

    Nabriva Summary = Developing novel antibiotics for serious infections = Pleuromutilins — new class of antibiotics in development for systemic use in humans + Novel mechanism of action with potent in vitro activity against multi-drug resistant strains + Proprietary platform and IP wholly owned by Nab

Source: SEC EDGAR · 6-K filed Nov 10, 2015

More decks from Nabriva Therapeutics AG